COFCO Biotechnology Co., Ltd.
000930.SZ · SHZ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.69 | 0.60 | 0.39 | -1.28 |
| FCF Yield | 1.98% | 8.89% | -3.78% | -1.12% |
| EV / EBITDA | 1,139.41 | 75.18 | 57.64 | -76.03 |
| Quality | ||||
| ROIC | -0.68% | 0.41% | 0.20% | -0.47% |
| Gross Margin | 7.15% | 6.78% | 8.08% | 0.41% |
| Cash Conversion Ratio | -15.03 | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -2.69% | 0.60% | 1.12% | 0.23% |
| Free Cash Flow Growth | -76.25% | 342.47% | -230.10% | -111.04% |
| Safety | ||||
| Net Debt / EBITDA | 148.69 | 12.36 | 13.84 | -14.50 |
| Interest Coverage | -2.15 | 3.45 | 1.99 | -0.98 |
| Efficiency | ||||
| Inventory Turnover | 1.95 | 1.47 | 1.27 | 1.77 |
| Cash Conversion Cycle | 62.02 | 66.64 | 83.12 | 62.31 |